LinkedIn Profile

Access Atara Biotherapeutics historical Linkedin company profile data on number of followers, employee headcount and more

Rows

Open dataset
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Headcount change in past 24 months Company Name Sector Industry
nasdaq:atra 8239333 Apr 21st, 2024 12:00AM Atara Biotherapeutics 35K 319.00 Open Apr 20th, 2024 10:58PM Apr 20th, 2024 10:58PM Atara Biotherapeutics Inc., is a leading allogeneic T-cell immunotherapy company pioneering the development of transformative off-the-shelf therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases.  With our lead program receiving marketing authorization in Europe, Atara is the most advanced allogeneic T-cell immunotherapy company and intends to rapidly deliver off-the-shelf treatments to patients with high unmet medical need. Our platform leverages the unique biology of EBV T cells and has the capability to treat a wide range of EBV-associated diseases, or other serious diseases through incorporation of engineered CARs (chimeric antigen receptors) or TCRs (T-cell receptors). Atara is applying this one platform, which does not require TCR or HLA gene editing, to create a robust pipeline including: tab-cel for Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD) and other EBV-driven diseases; ATA188, a T-cell immunotherapy targeting EBV antigens as a potential treatment for multiple sclerosis; and multiple next-generation chimeric antigen receptor T-cell (CAR-T) immunotherapies for both solid tumors and hematologic malignancies. Open biotechnology, immunotherapy, cell therapy, gene therapy, regenerative medicine, T-cells, cytotoxic T lymphocytes, CTLs, allogeneic, off the shelf, cancer, oncology, immuno-oncology, hematology, immunology, autoimmune diseases, multiple sclerosis, MS, Epstein-Barr virus, EBV, post-transplant lymphoproliferative disorder, PTLD, nasopharyngeal carcinoma, Cytomegalovirus, CMV, oncoviruses, bone marrow transplant, stem cell transplant, solid organ transplant, lymphoma, secondary lymphoma, secondary malignancy, lymphoproliferative disorders, EBV lymphoma, Atara Bio, Atara, ATRA, CAR T, solid tumors, Allogeneic CD19 CAR T, Allogeneic EBV CAR T-cell platform, Allogeneic CAR T-cell therapies, and progressive multiple sclerosis Open 2380 Conejo Spectrum St Thousand Oaks CA US 91320 Atara Biotherapeutics Health Care Pharmaceuticals & Biotechnology
nasdaq:atra 8239333 Apr 20th, 2024 12:00AM Atara Biotherapeutics 35K 319.00 Open Apr 19th, 2024 10:55PM Apr 20th, 2024 04:36PM Atara Biotherapeutics Inc., is a leading allogeneic T-cell immunotherapy company pioneering the development of transformative off-the-shelf therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases.  With our lead program receiving marketing authorization in Europe, Atara is the most advanced allogeneic T-cell immunotherapy company and intends to rapidly deliver off-the-shelf treatments to patients with high unmet medical need. Our platform leverages the unique biology of EBV T cells and has the capability to treat a wide range of EBV-associated diseases, or other serious diseases through incorporation of engineered CARs (chimeric antigen receptors) or TCRs (T-cell receptors). Atara is applying this one platform, which does not require TCR or HLA gene editing, to create a robust pipeline including: tab-cel for Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD) and other EBV-driven diseases; ATA188, a T-cell immunotherapy targeting EBV antigens as a potential treatment for multiple sclerosis; and multiple next-generation chimeric antigen receptor T-cell (CAR-T) immunotherapies for both solid tumors and hematologic malignancies. Open biotechnology, immunotherapy, cell therapy, gene therapy, regenerative medicine, T-cells, cytotoxic T lymphocytes, CTLs, allogeneic, off the shelf, cancer, oncology, immuno-oncology, hematology, immunology, autoimmune diseases, multiple sclerosis, MS, Epstein-Barr virus, EBV, post-transplant lymphoproliferative disorder, PTLD, nasopharyngeal carcinoma, Cytomegalovirus, CMV, oncoviruses, bone marrow transplant, stem cell transplant, solid organ transplant, lymphoma, secondary lymphoma, secondary malignancy, lymphoproliferative disorders, EBV lymphoma, Atara Bio, Atara, ATRA, CAR T, solid tumors, Allogeneic CD19 CAR T, Allogeneic EBV CAR T-cell platform, Allogeneic CAR T-cell therapies, and progressive multiple sclerosis Open 2380 Conejo Spectrum St Thousand Oaks CA US 91320 Atara Biotherapeutics Health Care Pharmaceuticals & Biotechnology
nasdaq:atra 8239333 Apr 19th, 2024 12:00AM Atara Biotherapeutics 35K 319.00 Open Apr 18th, 2024 11:02PM Apr 18th, 2024 11:02PM Atara Biotherapeutics Inc., is a leading allogeneic T-cell immunotherapy company pioneering the development of transformative off-the-shelf therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases.  With our lead program receiving marketing authorization in Europe, Atara is the most advanced allogeneic T-cell immunotherapy company and intends to rapidly deliver off-the-shelf treatments to patients with high unmet medical need. Our platform leverages the unique biology of EBV T cells and has the capability to treat a wide range of EBV-associated diseases, or other serious diseases through incorporation of engineered CARs (chimeric antigen receptors) or TCRs (T-cell receptors). Atara is applying this one platform, which does not require TCR or HLA gene editing, to create a robust pipeline including: tab-cel for Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD) and other EBV-driven diseases; ATA188, a T-cell immunotherapy targeting EBV antigens as a potential treatment for multiple sclerosis; and multiple next-generation chimeric antigen receptor T-cell (CAR-T) immunotherapies for both solid tumors and hematologic malignancies. Open biotechnology, immunotherapy, cell therapy, gene therapy, regenerative medicine, T-cells, cytotoxic T lymphocytes, CTLs, allogeneic, off the shelf, cancer, oncology, immuno-oncology, hematology, immunology, autoimmune diseases, multiple sclerosis, MS, Epstein-Barr virus, EBV, post-transplant lymphoproliferative disorder, PTLD, nasopharyngeal carcinoma, Cytomegalovirus, CMV, oncoviruses, bone marrow transplant, stem cell transplant, solid organ transplant, lymphoma, secondary lymphoma, secondary malignancy, lymphoproliferative disorders, EBV lymphoma, Atara Bio, Atara, ATRA, CAR T, solid tumors, Allogeneic CD19 CAR T, Allogeneic EBV CAR T-cell platform, Allogeneic CAR T-cell therapies, and progressive multiple sclerosis Open 2380 Conejo Spectrum St Thousand Oaks CA US 91320 Atara Biotherapeutics Health Care Pharmaceuticals & Biotechnology
nasdaq:atra 8239333 Apr 18th, 2024 12:00AM Atara Biotherapeutics 35K 319.00 Open Apr 17th, 2024 11:01PM Apr 18th, 2024 05:56PM Atara Biotherapeutics Inc., is a leading allogeneic T-cell immunotherapy company pioneering the development of transformative off-the-shelf therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases.  With our lead program receiving marketing authorization in Europe, Atara is the most advanced allogeneic T-cell immunotherapy company and intends to rapidly deliver off-the-shelf treatments to patients with high unmet medical need. Our platform leverages the unique biology of EBV T cells and has the capability to treat a wide range of EBV-associated diseases, or other serious diseases through incorporation of engineered CARs (chimeric antigen receptors) or TCRs (T-cell receptors). Atara is applying this one platform, which does not require TCR or HLA gene editing, to create a robust pipeline including: tab-cel for Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD) and other EBV-driven diseases; ATA188, a T-cell immunotherapy targeting EBV antigens as a potential treatment for multiple sclerosis; and multiple next-generation chimeric antigen receptor T-cell (CAR-T) immunotherapies for both solid tumors and hematologic malignancies. Open biotechnology, immunotherapy, cell therapy, gene therapy, regenerative medicine, T-cells, cytotoxic T lymphocytes, CTLs, allogeneic, off the shelf, cancer, oncology, immuno-oncology, hematology, immunology, autoimmune diseases, multiple sclerosis, MS, Epstein-Barr virus, EBV, post-transplant lymphoproliferative disorder, PTLD, nasopharyngeal carcinoma, Cytomegalovirus, CMV, oncoviruses, bone marrow transplant, stem cell transplant, solid organ transplant, lymphoma, secondary lymphoma, secondary malignancy, lymphoproliferative disorders, EBV lymphoma, Atara Bio, Atara, ATRA, CAR T, solid tumors, Allogeneic CD19 CAR T, Allogeneic EBV CAR T-cell platform, Allogeneic CAR T-cell therapies, and progressive multiple sclerosis Open 2380 Conejo Spectrum St Thousand Oaks CA US 91320 Atara Biotherapeutics Health Care Pharmaceuticals & Biotechnology
nasdaq:atra 8239333 Apr 17th, 2024 12:00AM Atara Biotherapeutics 35K 319.00 Open Apr 16th, 2024 10:45PM Apr 17th, 2024 02:19PM Atara Biotherapeutics Inc., is a leading allogeneic T-cell immunotherapy company pioneering the development of transformative off-the-shelf therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases.  With our lead program receiving marketing authorization in Europe, Atara is the most advanced allogeneic T-cell immunotherapy company and intends to rapidly deliver off-the-shelf treatments to patients with high unmet medical need. Our platform leverages the unique biology of EBV T cells and has the capability to treat a wide range of EBV-associated diseases, or other serious diseases through incorporation of engineered CARs (chimeric antigen receptors) or TCRs (T-cell receptors). Atara is applying this one platform, which does not require TCR or HLA gene editing, to create a robust pipeline including: tab-cel for Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD) and other EBV-driven diseases; ATA188, a T-cell immunotherapy targeting EBV antigens as a potential treatment for multiple sclerosis; and multiple next-generation chimeric antigen receptor T-cell (CAR-T) immunotherapies for both solid tumors and hematologic malignancies. Open biotechnology, immunotherapy, cell therapy, gene therapy, regenerative medicine, T-cells, cytotoxic T lymphocytes, CTLs, allogeneic, off the shelf, cancer, oncology, immuno-oncology, hematology, immunology, autoimmune diseases, multiple sclerosis, MS, Epstein-Barr virus, EBV, post-transplant lymphoproliferative disorder, PTLD, nasopharyngeal carcinoma, Cytomegalovirus, CMV, oncoviruses, bone marrow transplant, stem cell transplant, solid organ transplant, lymphoma, secondary lymphoma, secondary malignancy, lymphoproliferative disorders, EBV lymphoma, Atara Bio, Atara, ATRA, CAR T, solid tumors, Allogeneic CD19 CAR T, Allogeneic EBV CAR T-cell platform, Allogeneic CAR T-cell therapies, and progressive multiple sclerosis Open 2380 Conejo Spectrum St Thousand Oaks CA US 91320 Atara Biotherapeutics Health Care Pharmaceuticals & Biotechnology
nasdaq:atra 8239333 Apr 16th, 2024 12:00AM Atara Biotherapeutics 35K 320.00 Open Apr 15th, 2024 10:43PM Apr 16th, 2024 10:36AM Atara Biotherapeutics Inc., is a leading allogeneic T-cell immunotherapy company pioneering the development of transformative off-the-shelf therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases.  With our lead program receiving marketing authorization in Europe, Atara is the most advanced allogeneic T-cell immunotherapy company and intends to rapidly deliver off-the-shelf treatments to patients with high unmet medical need. Our platform leverages the unique biology of EBV T cells and has the capability to treat a wide range of EBV-associated diseases, or other serious diseases through incorporation of engineered CARs (chimeric antigen receptors) or TCRs (T-cell receptors). Atara is applying this one platform, which does not require TCR or HLA gene editing, to create a robust pipeline including: tab-cel for Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD) and other EBV-driven diseases; ATA188, a T-cell immunotherapy targeting EBV antigens as a potential treatment for multiple sclerosis; and multiple next-generation chimeric antigen receptor T-cell (CAR-T) immunotherapies for both solid tumors and hematologic malignancies. Open biotechnology, immunotherapy, cell therapy, gene therapy, regenerative medicine, T-cells, cytotoxic T lymphocytes, CTLs, allogeneic, off the shelf, cancer, oncology, immuno-oncology, hematology, immunology, autoimmune diseases, multiple sclerosis, MS, Epstein-Barr virus, EBV, post-transplant lymphoproliferative disorder, PTLD, nasopharyngeal carcinoma, Cytomegalovirus, CMV, oncoviruses, bone marrow transplant, stem cell transplant, solid organ transplant, lymphoma, secondary lymphoma, secondary malignancy, lymphoproliferative disorders, EBV lymphoma, Atara Bio, Atara, ATRA, CAR T, solid tumors, Allogeneic CD19 CAR T, Allogeneic EBV CAR T-cell platform, Allogeneic CAR T-cell therapies, and progressive multiple sclerosis Open 2380 Conejo Spectrum St Thousand Oaks CA US 91320 Atara Biotherapeutics Health Care Pharmaceuticals & Biotechnology
nasdaq:atra 8239333 Apr 15th, 2024 12:00AM Atara Biotherapeutics 35K 320.00 Open Apr 14th, 2024 10:44PM Apr 15th, 2024 04:17PM Atara Biotherapeutics Inc., is a leading allogeneic T-cell immunotherapy company pioneering the development of transformative off-the-shelf therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases.  With our lead program receiving marketing authorization in Europe, Atara is the most advanced allogeneic T-cell immunotherapy company and intends to rapidly deliver off-the-shelf treatments to patients with high unmet medical need. Our platform leverages the unique biology of EBV T cells and has the capability to treat a wide range of EBV-associated diseases, or other serious diseases through incorporation of engineered CARs (chimeric antigen receptors) or TCRs (T-cell receptors). Atara is applying this one platform, which does not require TCR or HLA gene editing, to create a robust pipeline including: tab-cel for Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD) and other EBV-driven diseases; ATA188, a T-cell immunotherapy targeting EBV antigens as a potential treatment for multiple sclerosis; and multiple next-generation chimeric antigen receptor T-cell (CAR-T) immunotherapies for both solid tumors and hematologic malignancies. Open biotechnology, immunotherapy, cell therapy, gene therapy, regenerative medicine, T-cells, cytotoxic T lymphocytes, CTLs, allogeneic, off the shelf, cancer, oncology, immuno-oncology, hematology, immunology, autoimmune diseases, multiple sclerosis, MS, Epstein-Barr virus, EBV, post-transplant lymphoproliferative disorder, PTLD, nasopharyngeal carcinoma, Cytomegalovirus, CMV, oncoviruses, bone marrow transplant, stem cell transplant, solid organ transplant, lymphoma, secondary lymphoma, secondary malignancy, lymphoproliferative disorders, EBV lymphoma, Atara Bio, Atara, ATRA, CAR T, solid tumors, Allogeneic CD19 CAR T, Allogeneic EBV CAR T-cell platform, Allogeneic CAR T-cell therapies, and progressive multiple sclerosis Open 2380 Conejo Spectrum St Thousand Oaks CA US 91320 Atara Biotherapeutics Health Care Pharmaceuticals & Biotechnology
nasdaq:atra 8239333 Apr 14th, 2024 12:00AM Atara Biotherapeutics 35K 320.00 Open Apr 13th, 2024 10:38PM Apr 14th, 2024 10:36AM Atara Biotherapeutics Inc., is a leading allogeneic T-cell immunotherapy company pioneering the development of transformative off-the-shelf therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases.  With our lead program receiving marketing authorization in Europe, Atara is the most advanced allogeneic T-cell immunotherapy company and intends to rapidly deliver off-the-shelf treatments to patients with high unmet medical need. Our platform leverages the unique biology of EBV T cells and has the capability to treat a wide range of EBV-associated diseases, or other serious diseases through incorporation of engineered CARs (chimeric antigen receptors) or TCRs (T-cell receptors). Atara is applying this one platform, which does not require TCR or HLA gene editing, to create a robust pipeline including: tab-cel for Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD) and other EBV-driven diseases; ATA188, a T-cell immunotherapy targeting EBV antigens as a potential treatment for multiple sclerosis; and multiple next-generation chimeric antigen receptor T-cell (CAR-T) immunotherapies for both solid tumors and hematologic malignancies. Open biotechnology, immunotherapy, cell therapy, gene therapy, regenerative medicine, T-cells, cytotoxic T lymphocytes, CTLs, allogeneic, off the shelf, cancer, oncology, immuno-oncology, hematology, immunology, autoimmune diseases, multiple sclerosis, MS, Epstein-Barr virus, EBV, post-transplant lymphoproliferative disorder, PTLD, nasopharyngeal carcinoma, Cytomegalovirus, CMV, oncoviruses, bone marrow transplant, stem cell transplant, solid organ transplant, lymphoma, secondary lymphoma, secondary malignancy, lymphoproliferative disorders, EBV lymphoma, Atara Bio, Atara, ATRA, CAR T, solid tumors, Allogeneic CD19 CAR T, Allogeneic EBV CAR T-cell platform, Allogeneic CAR T-cell therapies, and progressive multiple sclerosis Open 2380 Conejo Spectrum St Thousand Oaks CA US 91320 Atara Biotherapeutics Health Care Pharmaceuticals & Biotechnology
nasdaq:atra 8239333 Apr 13th, 2024 12:00AM Atara Biotherapeutics 35K 322.00 Open Apr 12th, 2024 10:28PM Apr 13th, 2024 11:04AM Atara Biotherapeutics Inc., is a leading allogeneic T-cell immunotherapy company pioneering the development of transformative off-the-shelf therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases.  With our lead program receiving marketing authorization in Europe, Atara is the most advanced allogeneic T-cell immunotherapy company and intends to rapidly deliver off-the-shelf treatments to patients with high unmet medical need. Our platform leverages the unique biology of EBV T cells and has the capability to treat a wide range of EBV-associated diseases, or other serious diseases through incorporation of engineered CARs (chimeric antigen receptors) or TCRs (T-cell receptors). Atara is applying this one platform, which does not require TCR or HLA gene editing, to create a robust pipeline including: tab-cel for Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD) and other EBV-driven diseases; ATA188, a T-cell immunotherapy targeting EBV antigens as a potential treatment for multiple sclerosis; and multiple next-generation chimeric antigen receptor T-cell (CAR-T) immunotherapies for both solid tumors and hematologic malignancies. Open biotechnology, immunotherapy, cell therapy, gene therapy, regenerative medicine, T-cells, cytotoxic T lymphocytes, CTLs, allogeneic, off the shelf, cancer, oncology, immuno-oncology, hematology, immunology, autoimmune diseases, multiple sclerosis, MS, Epstein-Barr virus, EBV, post-transplant lymphoproliferative disorder, PTLD, nasopharyngeal carcinoma, Cytomegalovirus, CMV, oncoviruses, bone marrow transplant, stem cell transplant, solid organ transplant, lymphoma, secondary lymphoma, secondary malignancy, lymphoproliferative disorders, EBV lymphoma, Atara Bio, Atara, ATRA, CAR T, solid tumors, Allogeneic CD19 CAR T, Allogeneic EBV CAR T-cell platform, Allogeneic CAR T-cell therapies, and progressive multiple sclerosis Open 2380 Conejo Spectrum St Thousand Oaks CA US 91320 Atara Biotherapeutics Health Care Pharmaceuticals & Biotechnology
nasdaq:atra 8239333 Apr 12th, 2024 12:00AM Atara Biotherapeutics 35K 325.00 Open Apr 11th, 2024 10:32PM Apr 12th, 2024 07:59AM Atara Biotherapeutics Inc., is a leading allogeneic T-cell immunotherapy company pioneering the development of transformative off-the-shelf therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases.  With our lead program receiving marketing authorization in Europe, Atara is the most advanced allogeneic T-cell immunotherapy company and intends to rapidly deliver off-the-shelf treatments to patients with high unmet medical need. Our platform leverages the unique biology of EBV T cells and has the capability to treat a wide range of EBV-associated diseases, or other serious diseases through incorporation of engineered CARs (chimeric antigen receptors) or TCRs (T-cell receptors). Atara is applying this one platform, which does not require TCR or HLA gene editing, to create a robust pipeline including: tab-cel for Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD) and other EBV-driven diseases; ATA188, a T-cell immunotherapy targeting EBV antigens as a potential treatment for multiple sclerosis; and multiple next-generation chimeric antigen receptor T-cell (CAR-T) immunotherapies for both solid tumors and hematologic malignancies. Open biotechnology, immunotherapy, cell therapy, gene therapy, regenerative medicine, T-cells, cytotoxic T lymphocytes, CTLs, allogeneic, off the shelf, cancer, oncology, immuno-oncology, hematology, immunology, autoimmune diseases, multiple sclerosis, MS, Epstein-Barr virus, EBV, post-transplant lymphoproliferative disorder, PTLD, nasopharyngeal carcinoma, Cytomegalovirus, CMV, oncoviruses, bone marrow transplant, stem cell transplant, solid organ transplant, lymphoma, secondary lymphoma, secondary malignancy, lymphoproliferative disorders, EBV lymphoma, Atara Bio, Atara, ATRA, CAR T, solid tumors, Allogeneic CD19 CAR T, Allogeneic EBV CAR T-cell platform, Allogeneic CAR T-cell therapies, and progressive multiple sclerosis Open 2380 Conejo Spectrum St Thousand Oaks CA US 91320 Atara Biotherapeutics Health Care Pharmaceuticals & Biotechnology

Request a demo to view additional historical data, and much more.

Request Demo

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.